Ocular Therapeutix Q2 revenue falls 18% to $13.5M; net loss $67.8M; SOL-1 data Q1 2026

OCULAR THERAPEUTIX, INC

2025-Q2 EPS reported -$0.77 revenue$24,156,000

Q2 net revenue $13.5M, down 18% YoY; DEXTENZA unit sales up 5% but net revenue pressured by reimbursement challenges.
Net loss $67.8M ($0.39/share) vs $43.8M ($0.26) YoY; R&D spend $51.1M (up 77%) driven by SOL trial costs.
Cash $391.1M; raised ~$97M via ATM in June; runway into 2028, well beyond SOL-1 and SOL-R data.
SOL-1 Phase 3 wet AMD top-line data on track for Q1 2026; SOL-R data expected 1H 2027 with streamlined rescue criteria.
Received FDA feedback on NPDR/DME program; Investor Day Sept 30 in NYC to detail strategy and commercial outlook.

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.